Eravacycline for the treatment of patients with bacterial infections.

Article Details

Citation
Copy to clipboard

Thakare R, Dasgupta A, Chopra S

Eravacycline for the treatment of patients with bacterial infections.

Drugs Today (Barc). 2018 Apr;54(4):245-254. doi: 10.1358/dot.2018.54.4.2800623.

PubMed ID
29869646 [ View in PubMed
]
Abstract

Eravacycline is a novel, broad-spectrum, synthetic fluorocycline antibiotic for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) due to multidrug-resistant Gram-positive, Gram-negative and anaerobic bacteria that has demonstrated superior potency to that of currently marketed antibiotics. Tetraphase Pharmaceuticals has submitted a new drug application for eravacycline for the treatment of cIAI due to drug-resistant bacteria. In 2013, the U.S. Food and Drug Administration (FDA) granted eravacycline qualified infectious disease product designation for the treatment of cUTI and cIAI.

DrugBank Data that Cites this Article

Drugs